SS INNOVATIONS INTL INC - SSII STOCK NEWS

SS Innovations has announced that its SSi Mantra Surgical Robotic System has been used to perform over 100 robotic cardiac surgeries, signaling significant market expansion. The SSi Mantra, featuring a unique fifth arm capability, has been utilized in more than 1000 procedures globally. The company anticipates FDA and CE Mark approvals by early 2025, further enhancing its market position. The global cardiac surgery device market is projected to grow from $17.1 billion in 2023 to $24.9 billion by 2030, while the surgical robotics market is expected to increase from $78.8 billion in 2022 to $188.8 billion by 2032. SS Innovations, through its comprehensive robotic cardiac surgery program, aims to provide less invasive, lower cost, and superior outcomes for patients worldwide.

SS Innovations International, Inc. (SSII) achieved a significant milestone by successfully performing the first infant pyeloplasty using its flagship SSi Mantra Surgical Robotic System. The procedure, led by Dr. Chandra Mohan Vaddi in Hyderabad, India, was a success on a 12-month-old baby. The SSi Mantra is the first surgical system made in India and is cost-effective with regulatory approval in India, Guatemala, and Indonesia. The system has been used in over 1000 surgical procedures across various specialties. SS Innovations is seeking regulatory approval in the US and EU by late 2024 or 2025.

SS Innovations International, Inc. (OTC: SSII) announced its Q1 2024 updates, highlighting the successful installations of the SSi Mantra Surgical Robotic System in India, launching cardiac surgery programs, selling 8 robotic systems with expected revenues of US $7 million, and achieving a milestone of 1,000 surgeries. Dr. Sudhir Srivastava also mentioned the training program at the World Laparoscopy Hospital, aiming to increase global adoption of their innovative robotic system.

SS Innovations International, Inc. (SSII) successfully conducts first-ever telesurgery using SSi Mantra Surgical Robotic System on an animal in India. The surgery involved four complex procedures and was led by world-class surgeons. The Company aims to revolutionize healthcare by making telesurgery accessible globally.

SS Innovations International, Inc. announces the successful performance of the world's first mitral valve replacement using the Made in India SSi Mantra Surgical Robotic System at the Narayana Institute of Cardiac Sciences. Dr. Nitin Kumar Rajput led the surgery, marking a significant milestone in cardiac care. The SSi Mantra system aims to offer minimally invasive solutions for cardiac patients, with regulatory approval in multiple countries and a growing market size. SS Innovations plans to expand regulatory approvals to the US and EU by 2024 or 2025.

SS Innovations International, Inc. conducted a groundbreaking live telesurgery demonstration at the inaugural SS Innovations Multi-Specialty Robotic Surgical Conference, showcasing their flagship robotic surgical system, the SSi Mantra™. The remote telesurgery demonstration included precisely suturing on a coronary artery less than one millimeter in diameter on a porcine heart model. The SSi Mantra™ Surgical Robotic System is the first surgical system to be made in India and has been granted regulatory approval in India and Guatemala, with more than 650 surgical procedures performed using the system to date.

SS Innovations International, Inc. (SSII) has filed a pre-submission application with the FDA for its SSi Mantra™ Surgical Robotic System, receiving acknowledgment from the CDRH. The company is working towards obtaining approvals in the United States and Europe, having already obtained regulatory approval in India and Guatemala. The SSi Mantra™ is the first surgical system made in India and is cost-effective with broad-spectrum surgical applications, including cardiac surgery.

SS Innovations International, Inc. (SSII) has partnered with Medikabazaar, a leading medical equipment supplier in India, to facilitate sales of its flagship SSi Mantra Surgical Robotic System to hospitals and medical facilities across India. The partnership aims to make robotic surgery affordable and accessible to a global population, with the SSi Mantra Surgical Robotic System being the first surgical system made in India, granted regulatory approval in India and Guatemala, and clinically validated in more than 40 different types of surgical procedures. The system is cost-effective with broad-spectrum surgical applications, including cardiac surgery, and has already been used in over 650 surgical procedures. SS Innovations is also seeking regulatory approvals in the United States and Europe, expected to be received in 2024 and 2025.

SS Innovations International, Inc. hosted the inaugural SS Innovations Multi-Specialty Robotic Surgical Conference (SMRSC) in India, showcasing the SSi Mantra Surgical Robotic System. The event featured 13 live surgeries, panel discussions, and scientific sessions, with a focus on the integration of Artificial Intelligence in surgery and the pursuit of sustainable tele-surgery. The SSi Mantra is the first surgical robotic system made in India, with regulatory approval and clinical validation in over 40 different surgical procedures. The company is seeking regulatory approvals in the United States and Europe in 2024 and 2025.